Abstract
Live virus vaccines have in many cases proven to be an extremely effective tool for the prevention of viral diseases 1, 2 . However, the production of conventional live vaccines in eukaryotic cell cultures has many disadvantages, including the potential for contamination with adventitious agents 3 and genetic alterations during propagation, making it necessary to do extensive testing before distribution 4, 5 . Based on results obtained with a flavivirus 6 (tick-borne encephalitis virus) in an experimental animal system, we propose a novel live attenuated virus vaccination strategy consisting of the application of in vitro -synthesized infectious RNA instead of the live virus itself. When administered using the GeneGun, less than 1 ng of RNA was required to initiate replication of virus that was attenuated by a specifically engineered deletion 7 and this induced a protective immunity in laboratory mice. Because this approach uses RNA, it does not have the potential drawbacks of DNA vaccines 8, 9, 10 and thus combines the advantages of conventional live virus vaccines 1, 2 (for example, mimicking natural infection and inducing long-lasting immunity) with those of nucleic acid-based vaccines 2, 8, 11, 12 (for example, ease of production without a requirement for eukaryotic cell culture, stability and purity).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ada, G. Overview of vaccines. Mol. Biotechnol. 8, 123– 134 (1997).
Liu, M.A. Vaccine developments. Nature Med. 4, 515–519 (1998).
Petricciani, J.C. Regulatory philosophy and acceptability of cells for the production of biologicals. Dev. Biol. Stand. 75, 9– 15 (1991).
Parkman, P.D. & Hardegree, M.C. in Vaccines 2nd edn. (eds. Plotkin, S.A. & Mortimer, E.A.) 889– 901 (W.B. Saunders, Philadelphia, Pennsylvania, 1994).
Wood, D.J. & Macadam, A.J. Laboratory tests for live attenuated poliovirus vaccines. Biologicals 25, 3– 15 (1997).
Wengler, G. et al. in Virus Taxonomy. Sixth Report of the International Committee on Taxonomy of Viruses (eds. Murphy, F.A. et al.) 415– 427 (Springer-Verlag, Vienna, Austria,1995).
Mandl, C.W. et al. Spontaneous and engineered deletion in the 3´ noncoding region of tick-borne encephalitis virus: Construction of highly attenuated mutants of a flavivirus. J. Virol. 72, 2132–2140 (1998).
Vogel, F.R. & Sarver, N. Nucleic acid vaccines. Clin. Microbiol. Rev. 8, 406–410 (1995).
Manickan, E., Karem, K.L. & Rouse, B.T. DNA vaccines – a modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17, 139–154 (1997).
Gregoriadis, G. Genetic vaccines: strategies for optimization. Pharm. Res. 15, 661–670 (1998).
Donnelly, J.J., Ulmer, J.B., Shiver, J.W. & Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 15, 617–648 (1997).
Chattergoon, M., Boyer, J. & Weiner, D.B. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J. 11, 753– 763 (1997).
Rice, C.M. in Fields Virology, 3rd edn. (eds. Fields, B.N. et al. ) 931–960 (Lippincott-Raven, Philadelphia, Pennsylvania, 1996).
Mandl, C.W., Ecker, M., Holzmann, H., Kunz, C. & Heinz, F.X. Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr. J. Gen. Virol. 78, 1049– 1057 (1997).
Conry, R.M., LoBuglio, A.F. & Curiel, D.T. Polynucleotide-mediated immunization therapy of cancer. Semin. Oncol. 23, 135– 147 (1996).
Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364– 369 (1998).
Qiu, P., Ziegelhoffer, P., Sun, J. & Yang, N.S. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 3, 262–268 (1996).
Zhou, X. et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12, 1510–1514 (1994).
Heinz,, F.X., Tuma, W., Guirakhoo, F. & Kunz, C. A model study of the use of monoclonal antibodies in capture enzyme immunoassays for antigen quantification exploiting the epitope map of tick-borne encephalitis virus. J. Biol. Standard. 14, 133– 141 (1986).
Reed, J.L. & Muench, H. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27, 493 (1938).
Acknowledgements
We thank H. Dippe and M. Wilfinger for their technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mandl, C., Aberle, J., Aberle, S. et al. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 4, 1438–1440 (1998). https://doi.org/10.1038/4031
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/4031
- Springer Nature America, Inc.
This article is cited by
-
N1-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes
Cytotechnology (2022)
-
Variability in the 3′ untranslated regions of the genomes of the different tick-borne encephalitis virus subtypes
Virus Genes (2019)
-
mRNA vaccines — a new era in vaccinology
Nature Reviews Drug Discovery (2018)
-
Tools for translation: non-viral materials for therapeutic mRNA delivery
Nature Reviews Materials (2017)
-
mRNA-based therapeutics — developing a new class of drugs
Nature Reviews Drug Discovery (2014)